Mode
Text Size
Log in / Sign up
Phase 4 Completed N=577 Randomized Double-blind Treatment

Benzocaine Gel Toothache Dose-Response Study

Source: ClinicalTrials.gov NCT00474175 ↗
Enrolled (actual)
577
Serious AEs
0.0%
Results posted
Jan 2012
Primary outcomePrimary: Percentage of Participants With a Response — 70.4; 80.7; 87.3 Percentage of participants — p=<0.001

Summary

To evaluate the efficacy and safety of benzocaine gel products for the relief of toothache and to assess the subject's compliance with proposed label directions.

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants With a Response
70.4; 80.7; 87.3 <0.001 sig
SECONDARY
Time to First Confirmed Perceptible Relief
2.0; 1.4; 1.1 <0.001 sig
SECONDARY
Time to Meaningful Relief
8.5; 4.4; 3.2 <0.001 sig
SECONDARY
Duration of Effect
NA; NA; NA
SECONDARY
Sum of Pain Relief Combined With Pain Intensity Differences (SPRID) Scores
3.1; 3.4; 3.6; 5.9; 6.4; 6.7 0.035 sig
SECONDARY
Time to Dropping Out Due to Lack of Efficacy or Rescue Medication
NA; NA; NA
SECONDARY
Pain Relief Combined With Pain Intensity Difference (PRID) Scores
2.72; 3.25; 3.66; 3.08; 3.56; 3.88 <0.001 sig
SECONDARY
Global Satisfaction Assessment
2.1; 2.5; 2.5 0.035 sig

Eligibility Criteria

Inclusion Criteria

  • Males or females at least 12 years of age.
  • Presence of spontaneous toothache pain in only one permanent tooth. Toothache pain is due only to an open tooth cavity and only as a result of dental caries, loss of a restoration or tooth fracture.
  • To qualify for the study, the subject must have a rating of at least moderate pain on the Dental Pain Scale (DPS) and a score of at least 50 mm on the Visual Analog Scale. To be included in the moderate pain stratum, the subjects must have a rating of moderate pain in the DPS and to be included in the severe pain stratum the subjects must have a rating of severe pain in the DPS.
  • Females who are neither pregnant, as verified by a urine-based pregnancy test, nor breast-feeding.
  • Female subjects of childbearing potential and those who are post-menopausal for less than 2 years must be using a medically approved method of contraception (i.e., oral, transdermal or implanted contraceptive devices, intrauterine device, diaphragm, condom, abstinence, or surgical sterility).
  • Subjects must be reliable, cooperative and of adequate intelligence to read and understand the rating scales and other study instructions.
  • Subjects must be able to read, comprehend, and sign the consent form. Minors will provide assent to study participation if age appropriate. Parent/legal guardian must be able to read, comprehend, and sign the informed consent form.

Exclusion Criteria

  • Presence of spontaneous toothache pain in a primary tooth. Presence of spontaneous toothache pain in more than one tooth. Presence of an open tooth cavity in a tooth adjacent to the painful tooth with the open tooth cavity.
  • Presence of concomitant oral pain due to any other condition such as: soft-tissue lesions (e.g., aphthous or traumatic ulcer, herpes labialis, acute necrotizing ulcerative gingivitis); or multiple hard-tissue (e.g., carious) lesions; pain due to other surgical procedures, injuries or dental surface sensitivity.
  • Presence of a periodontal abscess as diagnosed from an X-ray or clinical examination of the painful tooth.
  • Presence of glucose-6-phosphate dehydrogenase (G6PD) deficiency.
  • History of acute or chronic hemolytic anemia.
  • History of sensitivity or allergy to benzocaine or other local anesthetic agents.
  • Use of any short-acting oral or topical analgesic/ anesthetic product within 2 hours of enrollment or any long-acting Rx or OTC analgesic product within 4 hours of enrollment.
  • Use of an investigational drug or participation in an investigational study within the past 30 days.
  • Previous participation in this study.
  • Member or a relative of the study site staff or sponsor directly involved in the study.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00474175). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search